Suppr超能文献

发现并优化环己烷-1,4-二胺作为变构的 MALT1 抑制剂。

Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.

机构信息

Department of Medicinal Chemistry, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden.

Department of Medicinal Chemistry, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden.

出版信息

Eur J Med Chem. 2022 Jan 5;227:113925. doi: 10.1016/j.ejmech.2021.113925. Epub 2021 Oct 21.

Abstract

Inhibition of mucosa-associated lymphoid tissue lymphoma translocation protein-1 (MALT1) is a promising strategy to modulate NF-κB signaling, with the potential to treat B-cell lymphoma and autoimmune diseases. We describe the discovery and optimization of (1s,4s)-N,N'-diaryl cyclohexane-1,4-diamines, a novel series of allosteric MALT1 inhibitors, resulting in compound 8 with single digit micromolar cell potency. X-ray analysis confirms that this compound binds to an induced allosteric site in MALT1. Compound 8 is highly selective and has an excellent in vivo rat PK profile with low clearance and high oral bioavailability, making it a promising lead for further optimization.

摘要

抑制黏膜相关淋巴组织淋巴瘤易位蛋白-1(MALT1)是调节 NF-κB 信号的一种很有前途的策略,具有治疗 B 细胞淋巴瘤和自身免疫性疾病的潜力。我们描述了(1s,4s)-N,N'-二芳基环己烷-1,4-二胺的发现和优化,这是一种新型的变构 MALT1 抑制剂系列,导致化合物 8 具有单个位数微摩尔的细胞效力。X 射线分析证实,该化合物与 MALT1 中的诱导变构位点结合。化合物 8 具有高度的选择性,在体内大鼠 PK 特征中具有低清除率和高口服生物利用度,使其成为进一步优化的有前途的先导化合物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验